- Home
- MDWD vs IMMP Comparison
MDWD vs IMMP Comparison
Compare MDWD & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- IMMP
- Stock Information
- Founded
- MDWD 2000
- IMMP 1987
- Country
- MDWD Israel
- IMMP Australia
- Employees
- MDWD N/A
- IMMP N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- MDWD Health Care
- IMMP Health Care
- Exchange
- MDWD Nasdaq
- IMMP Nasdaq
- Market Cap
- MDWD 208.2M
- IMMP 244.5M
- IPO Year
- MDWD 2014
- IMMP N/A
- Fundamental
- Price
- MDWD $20.47
- IMMP $1.69
- Analyst Decision
- MDWD Strong Buy
- IMMP Buy
- Analyst Count
- MDWD 2
- IMMP 1
- Target Price
- MDWD $35.00
- IMMP $7.00
- AVG Volume (30 Days)
- MDWD 50.6K
- IMMP 85.3K
- Earning Date
- MDWD 08-13-2025
- IMMP 02-27-2025
- Dividend Yield
- MDWD N/A
- IMMP N/A
- EPS Growth
- MDWD N/A
- IMMP N/A
- EPS
- MDWD N/A
- IMMP N/A
- Revenue
- MDWD $19,213,000.00
- IMMP $3,019,249.00
- Revenue This Year
- MDWD $20.80
- IMMP $50.37
- Revenue Next Year
- MDWD $26.92
- IMMP N/A
- P/E Ratio
- MDWD N/A
- IMMP N/A
- Revenue Growth
- MDWD N/A
- IMMP 24.11
- 52 Week Low
- MDWD $14.14
- IMMP $1.32
- 52 Week High
- MDWD $22.51
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- MDWD 55.68
- IMMP 48.66
- Support Level
- MDWD $19.07
- IMMP $1.64
- Resistance Level
- MDWD $21.26
- IMMP $1.74
- Average True Range (ATR)
- MDWD 0.69
- IMMP 0.07
- MACD
- MDWD 0.12
- IMMP 0.01
- Stochastic Oscillator
- MDWD 66.81
- IMMP 76.19
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.